Clinuvel Pharmaceuticals Ltd key statistics and ratios

In fiscal 2026, Clinuvel Pharmaceuticals Ltd had return on equity of 13.4%, an operating margin of 43.4%, debt equal to 0.0% of equity and a current ratio of 14.72. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Clinuvel Pharmaceuticals Ltd: financial ratios, annual
Fiscal year	2024Jun 2024	2025Jun 2025	2026Jun 2026
Gross margin	81.5%	81.2%	82.9%
Operating margin	49.3%	43.4%	43.4%
Net margin	40.3%	37.8%	36.0%
Free-cash-flow margin	34.7%	44.3%	18.4%
Return on equity	17.3%	15.8%	13.4%
Return on assets	—	13.1%	12.2%
Asset turnover	—	0.35	0.34
Current ratio	—	9.68	14.72
Debt to equity	—	0.0%	0.0%
Effective tax rate	29.7%	30.1%	29.2%
R&D as % of revenue	17.3%	21.6%	19.0%
Capital spending as % of revenue	6.3%	0.3%	1.6%
Free cash flow ÷ net income	86.1%	117.2%	51.1%
Dividends ÷ net income	6.8%	7.3%	7.2%
Dividends and buybacks ÷ free cash flow	10.4%	6.9%	14.1%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · June 30, 2026

What it owns · $204m

Short-term assets $197mLonger-term assets $7m

What it owes, and who funded it · $204m

Short-term liabilities $13mLonger-term liabilities $2mShareholders' equity $189m

Short-term assets cover short-term liabilities $197m of assets due within a year against $13m of liabilities due within a year.
Short-term assets cover long-term liabilities $197m short-term assets against $2m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Clinuvel Pharmaceuticals Ltd's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ABCL vs CUVL CUVL vs CYTK CUVL vs RXRX CUVL vs NTLA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Clinuvel Pharmaceuticals Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Clinuvel Pharmaceuticals Ltd.